A France-based specialty vaccine company announced its plans to accelerate pediatric development of the Lyme vaccine candidate, VLA15, in collaboration with Pfizer Inc.
Valneva SE stated in a press release the planned initiation of the study VLA15-221 will be in the first quarter of 2021, subject to regulatory approval.
Read More
